~~<i id='DAF1237620'><strike id='DAF1237620'><tt id='DAF1237620'><pre id='DAF1237620'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：entertainment 2025-09-27 20:33:39 Page View：9988

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Superbugs, antibiotic resistance get scrutiny in congress
Next article： The high cost of giving birth even with insurance

explore

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

A Greenpeace activist is fined for crash

FILE-TheGermanplayerslookonasaGreenpeaceparagliderlandsinthestadiumpriortotheEuro2020soccerchampions

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

Senate panel to vote on hospitals, PBMs, prisoner care

SarahSilbiger/GettyImagesWASHINGTON—TheSenateFinanceCommitteeplanstovoteNov.8onlegislationthatinclud